Black Rock Inc. Bellus Health Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$7.14 - $8.53 $376,849 - $450,213	-52,780 Reduced 5.73%	868,239 $6.25 Million
Q4 2022 Feb 13, 2023	BUY	$8.22 - $10.76 $574,898 - $752,543	69,939 Added 8.22%	921,019 $7.57 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $984,347 - $1.32 Million	109,983 Added 14.84%	851,080 $8.99 Million
Q2 2022 Aug 12, 2022	SELL	$6.46 - $10.02 $387,877 - $601,630	-60,043 Reduced 7.49%	741,097 $6.85 Million
Q1 2022 May 12, 2022	BUY	$5.56 - $7.99 $1.34 Million - $1.93 Million	241,327 Added 43.11%	801,140 $5.51 Million
Q4 2021 Feb 10, 2022	BUY	$5.26 - $8.3 $2.94 Million - $4.65 Million	559,813 New	559,813 $4.51 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.